The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 29, 2025

Filed:

Jan. 31, 2023
Applicant:

Children's Medical Center Corporation, Boston, MA (US);

Inventor:

Randolph S. Watnick, Newton, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2018.12); A61K 38/00 (2005.12); A61K 38/07 (2005.12); A61K 39/00 (2005.12); A61K 39/395 (2005.12); A61K 45/06 (2005.12); C07K 5/11 (2005.12); C07K 5/113 (2005.12); C07K 7/06 (2005.12); C07K 14/475 (2005.12); C07K 16/00 (2005.12); C12Q 1/6886 (2017.12); G01N 33/50 (2005.12); G01N 33/574 (2005.12); G01N 33/68 (2005.12); G01N 33/74 (2005.12);
U.S. Cl.
CPC ...
A61K 38/08 (2012.12); A61K 38/07 (2012.12); A61K 39/39591 (2012.12); A61K 45/06 (2012.12); C07K 5/1019 (2012.12); C07K 5/1021 (2012.12); C07K 7/06 (2012.12); C07K 14/475 (2012.12); C07K 16/00 (2012.12); C12Q 1/6886 (2012.12); G01N 33/5023 (2012.12); G01N 33/574 (2012.12); G01N 33/6893 (2012.12); G01N 33/74 (2012.12); A61K 38/00 (2012.12); A61K 2039/505 (2012.12); C07K 2319/30 (2012.12); C07K 2319/31 (2012.12); C12Q 2600/106 (2012.12); G01N 2800/52 (2012.12);
Abstract

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.


Find Patent Forward Citations

Loading…